Literature DB >> 30422185

Provision of Naloxone Without a Prescription by California Pharmacists 2 Years After Legislation Implementation.

Talia Puzantian1, James J Gasper2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30422185      PMCID： PMC6248130          DOI： 10.1001/jama.2018.12291

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Barriers and facilitators to dispensing of intranasal naloxone by pharmacists.

Authors:  Ludmila N Bakhireva; Adriana Bautista; Sandra Cano; Shikhar Shrestha; Amy M Bachyrycz; Theresa H Cruz
Journal:  Subst Abus       Date:  2017-12-05       Impact factor: 3.716

2.  Dispensing Naloxone Without a Prescription: Survey Evaluation of Ohio Pharmacists.

Authors:  Erin L Thompson; P S S Rao; Christopher Hayes; Catherine Purtill
Journal:  J Pharm Pract       Date:  2018-02-25

Review 3.  Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria.

Authors:  Rebecca McDonald; John Strang
Journal:  Addiction       Date:  2016-03-30       Impact factor: 6.526

4.  Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis.

Authors:  Alexander Y Walley; Ziming Xuan; H Holly Hackman; Emily Quinn; Maya Doe-Simkins; Amy Sorensen-Alawad; Sarah Ruiz; Al Ozonoff
Journal:  BMJ       Date:  2013-01-30
  4 in total
  17 in total

1.  Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.

Authors:  Elizabeth Donovan; Patricia Case; Jeffrey P Bratberg; Janette Baird; Dina Burstein; Alexander Y Walley; Traci C Green
Journal:  J Urban Health       Date:  2019-06       Impact factor: 3.671

2.  Opioid-Related Education Provided by Continuing Education Divisions at US Pharmacy Schools.

Authors:  Mandy L Renfro; Leticia R Moczygemba; Jennifer Baumgartner; Glen Baumgart; Lucas G Hill
Journal:  Am J Pharm Educ       Date:  2020-10       Impact factor: 2.047

3.  Evaluation of naloxone furnishing community pharmacies in San Francisco.

Authors:  Andy M Nguyen; Thomas E Kearney; Dorie E Apollonio
Journal:  J Am Pharm Assoc (2003)       Date:  2020-09-15

4.  Legal requirements and recommendations to prescribe naloxone.

Authors:  Rebecca L Haffajee; Samantha Cherney; Rosanna Smart
Journal:  Drug Alcohol Depend       Date:  2020-02-06       Impact factor: 4.492

Review 5.  The Association of State Opioid Misuse Prevention Policies With Patient- and Provider-Related Outcomes: A Scoping Review.

Authors:  Amanda I Mauri; Tarlise N Townsend; Rebecca L Haffajee
Journal:  Milbank Q       Date:  2019-12-04       Impact factor: 4.911

6.  Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.

Authors:  David Dadiomov; Maria Bolshakova; Melania Mikhaeilyan; Rebecca Trotzky-Sirr
Journal:  Harm Reduct J       Date:  2022-06-29

7.  Rates and correlates of medicine disposal program implementation at pharmacies in North Carolina: A longitudinal study, 2016-2021.

Authors:  Kathleen L Egan; Carol A Johnston; Jeffrey T Jackson; Samantha E Foster; Joseph G L Lee
Journal:  J Am Pharm Assoc (2003)       Date:  2022-03-08

8.  Commentary on Hill et al.: Breaking down barriers-increasing access to lifesaving opioid use disorder medications to save lives.

Authors:  Michael S Toce; Scott E Hadland
Journal:  Addiction       Date:  2021-01-06       Impact factor: 7.256

9.  Association of Opioid Overdose Risk Factors and Naloxone Prescribing in US Adults.

Authors:  Lewei Allison Lin; Chad M Brummett; Jennifer F Waljee; Michael J Englesbe; Vidhya Gunaseelan; Amy S B Bohnert
Journal:  J Gen Intern Med       Date:  2020-02       Impact factor: 5.128

10.  Effectiveness and implementability of state-level naloxone access policies: Expert consensus from an online modified-Delphi process.

Authors:  Rosanna Smart; Sean Grant
Journal:  Int J Drug Policy       Date:  2021-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.